merger

Artykuły - Merger (42)

  • VST ujawnia sekrety galaktyk

    VST ujawnia sekrety galaktyk

    Na tym gigantycznym zdjęciu gromady Galaktyk w Piecu o uwagę rywalizują niezliczone galaktyki, niektóre dostrzegalne jedynie jako drobne punkty świetlne, a inne dominujące na pierwszym planie. Jedną z nich jest galaktyka soczewkowata NGC 1316.
  • Notification for s signed contract for transformation through merger of Unipharm AD in Sopharma AD

    UNI - EN REPORT No78/2017Sopharma AD announces that on 14 September, 2017 in accordance with art. 262e and the following from the Commercial Code Unipharm AD and Sopharma AD signed a contract for transformation through merger of Unipharm AD in Sopharma AD and the respective consequences following that decision. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a r
  • Decision of initiation of a procedure for transformation through merger of Unipharm AD in Sopharma AD

    UNI - EN REPORT No77/2017The Board of Directors of Sopharma notifies that it took a decision to initiate a procedure for merging Unipharm AD, VAT number 831537465 based in the city of Sofia on 3, “Trayko Stanoev” Str. into Sopharma AD, under the regulation of the Commercial Code and art. 122 and the following of the Law on Public Offering of Securities and chooses “Elana Trading” AD VAT number 831470130, based on 5, Lachezar Stanchev Str. for a consultant in relation to the merger.
  • Notification for transformation throough merger of Medika AD in Sopharma AD

    UNI - EN REPORT No61/2017Sopharma AD notifies that the transformation through merger of Medika AD in Sopharma AD has been registered with the Commercial Register with number 20170808155501.
  • Notification for the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals

    UNI - EN REPORT No58/2017Sopharma AD notifies that the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals was successfully closed today and as a result of which the stockholders of Achieve have become the majority stockholders of OncoGenex. OncoGenex has been renamed Achieve Life Sciences (NASDAQ: ACHV). The company announced that "Cytisine is a drug of global public health importance and the transition of Achieve to the public markets is a critical step in advan
  • Notification for the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals

    UNI - EN REPORT No58/2017Sopharma AD notifies that the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals was successfully closed today and as a result of which the stockholders of Achieve have become the majority stockholders of OncoGenex. OncoGenex has been renamed Achieve Life Sciences (NASDAQ: ACHV). The company announced that "Cytisine is a drug of global public health importance and the transition of Achieve to the public markets is a critical step in advan
  • Notification for merger of Achieve Lifesciences and Oncogenex

    UNI - EN REPORT No44/2017We are pleased to announce that the next step in the process of merging Achieve Lifesciences and Oncogenex has been completed with the approval of the merger by the US SEC. OncoGenex will hold a special shareholder meeting on 1 August 2017 to vote the merger. Shortly after the newly formed entity will trade on NASDAQ stock exchange under the ticker symbol ACHV.
  • Ad-hoc announcement: IMMOFINANZ AG: Agreement in principle to settle the legal proceedings over the review of the exchange ratio applied to the merger of IMMOEAST and IMMOFINANZ

    UNI - EN REPORT No10/2017
  • Notification for a signed annex to the Contract for transformation through merger - Medica AD

    UNI - EN REPORT No12/2017Sopharma AD (the “Company”) notifies that on 20 March 2017 Sopharma AD, Sofia, UIC 831902088 and Medica AD, Sofia, UIC 000000993 signed an annex to the Contract for transformation through merger reflecting the comments by the FSC. All documents will be filed with the FSC for approval pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA) after an independent certified evaluator prepares a report. As a result of the merger, all shareholders
  • Notification for signed contract for merger between Sopharma AD and Medica AD

    UNI - EN REPORT No6/2017Sopharma AD (the “Company”) notifies that on 13 February 2017 the Contract for merger, as well as reports of the management bodies of the companies involved in the transformation of the company under art. 262i of the CA and the report of the examiner under art. 262m of the CA for transformation through merger between Sopharma AD, Sofia, UIC 831902088 and Medica AD, Kazanluk, UIC 000000993 were filed with the FSC for approval pursuant to art. 124, par. 1 of the Pub